Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
SWOT Snapshot (Quick Take): Strength: First-in-class weekly insulin with strong efficacy Weakness: Limited dosing flexibility vs daily insulin Opportunity: Adherence-driven market expansion & GLP-1 combos Threat: Physician inertia + competitive long-acting pipelines
Yanfang Xu was supported by Fujian Research and Training Grants for Young and Middle-aged Leaders in Healthcare, and the Outstanding Young Talents Program of the First Affiliated Hospital of Fujian Medical University (YJCQN-A-XYF2021)
Lancet (2015) 386:154655
That reduction in itself could increase lifespan ( the length of time an organism lives, or total lifespan
Its effects are gradual but deeply systemic, making it particularly relevant for those focused on longevity and performance
US$ 27.26
US$ 23.51
US$ 20.75
US$ 27.98
